Skip to main
BNTC

BNTC Stock Forecast & Price Target

BNTC Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Benitec Biopharma Inc. is positioned favorably due to the promising results from its ongoing clinical trials for BB-301, which indicate a potential for accelerated regulatory pathways and premium pricing opportunities based on the therapy's value proposition. The company has reported a 100% responder rate among participants, alongside evidence of sustained clinical improvement in swallowing capabilities, raising the probability of approval to 45%. Financially, Benitec Biopharma's robust balance sheet, with $94.5 million in cash, indicates strong capital support for the continued development of BB-301, enhancing the company's prospects for success in pivotal clinical assessments.

Bears say

Benitec Biopharma reported a net loss of $0.21 per share for F1Q26, which was an improvement compared to the forecasted $0.41 loss, primarily affected by a higher-than-expected number of shares outstanding. Despite this adjustment, the company faces substantial risks, including the possibility of slower-than-expected progress in clinical trials for its lead candidate BB-301, negative trial data, challenges in obtaining regulatory approval, and potential market uptake issues. Furthermore, projected losses for fiscal 2026 remain significant at $1.00 per share, highlighting concerns regarding long-term viability and potential equity dilution risks.

BNTC has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Benitec Biopharma Limited Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Benitec Biopharma Limited Sponsored ADR (BNTC) Forecast

Analysts have given BNTC a Buy based on their latest research and market trends.

According to 4 analysts, BNTC has a Buy consensus rating as of Apr 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Benitec Biopharma Limited Sponsored ADR (BNTC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.